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ABSTRACT 
 
Pharmacokinetic profiles of probucol were evaluated after oral 
administration of the various nano-suspensions in rats.  Probucol nanoparticles 
were prepared by co-grinding with various molecular weights of 
polyvinylpyrrolidone (PVP K12, PVP K17 and PVP K30) and sodium dodecyl 
sulfate (SDS).  The average particle sizes of probucol after dispersing the 
ternary ground mixtures (GMs), probucol/PVP K12/SDS, probucol/PVP 
K17/SDS and probucol/PVP K30/SDS into distilled water were 28, 75 and 89 
nm, respectively, compared to the unprocessed probucol was 27 µm.  The 
ternary GM suspensions with PVP K17/SDS and PVP K30/SDS were stable at 
25 °C.  However the particle size of probucol from the ternary GM with PVP 
K12/SDS gradually increased was attributable to insufficient surface coverage 
of the nanoparticles with PVP K12-SDS micelle complex.  Pharmacokinetic 
profiles of probucol indicated that variation in particle surface condition 
covered with PVP and SDS in addition to the particle size affected the 
improvement of in vivo absorption of probucol.  The ternary GM with PVP 
K12/SDS exhibited a superior improvement of probucol absorption compared to 
the GMs with PVP K17/SDS and PVP K30/SDS.  The binary GM with PVP or 
SDS and physical mixtures with PVP and/or SDS did not show significant 
differences in the area under the plasma concentration-time curve compared to 
the unprocessed probucol.  In conclusion, preparation of probucol 
nanoparticles by co-grinding with PVP K12 and SDS could be a promising 
method for bioavailability enhancement. 
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INTRODUCTION 
 
Probucol, 4,4’-{(l-methylethylidene)bis(thio)}-bis{2,6-bis(l,l-dimethylethyl)}phenol, is 
mainly used as a cholesterol-lowering agent.1, 2)  Various studies suggest that 
probucol lowers serum cholesterol by increasing the fractional rate of low 
density lipoprotein (LDL) catabolism in the final metabolic pathway for 
cholesterol elimination from the body.3-5)  Probucol also inhibits the oxidation 
and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis.3, 6-8)  
Probucol can not be injected intravenously due to the poor water solubility (5 
ng/mL at 25 °C).3, 9, 10)  Since The bioavailability of probucol is very poor ( up 
to 6%), LD50 of probucol in rat is 5 g/kg through oral administration.11)  The 
tablet form of probucol is absorbed at different rates and in different amounts 
depending on the individual patients.3)  When probucol was co-administered 
with arachis oil, the absorption enhancement of probucol in rats was 
observed.12)  Thus, the formulation seems to be important to improve the 
bioavailability. 
Reducing the particle size is one of the ideas to improve the 
bioavailability of drugs with poor absorption.13, 14)  Several cutting-edge 
technologies such as high pressure homogenization, spray dry, supercritical 
fluid processing, precipitation techniques and grinding are currently utilized to 
generate drug nanoparticles.15-24)  Co-grinding, where a drug is ground together 
with excipients, is a promising method for an effective reduction of particle size. 
A certain number of studies revealed that the co-ground mixture 
enhanced dissolution, resulting in the improvement of oral absorption and 
- 3 - 
bioavailability.25-28)  Wet co-grinding method has been known as an effective 
method to produce stable nanosuspensions.29-33)  Liversidge and Cundy 
proposed a preparation method for crystalline nanoparticle by wet co-grinding 
of danazol with polyvinylpyrrolidone (PVP).29)  Oral absorption of poorly 
water-soluble drugs in nanocrystal form was remarkably improved.29, 30)  
However, the wet process may cause drug degradation by hydrolysis during the 
preparation.  In addition, a drying process should be required to prepare the 
solid dosage form.  Compared with the wet co-grinding method, the dry 
co-grinding process has some advantages for solid pharmaceutical applications 
due to its simple preparation with free solvents.  However, in vivo absorption 
experiments have been rarely reported. 
Our previous studies demonstrated that drug nanoparticle was 
successfully produced by the dry co-grinding of a poorly water-soluble drug 
with polymer and surfactant.34-36)  The combined use of polymer and a 
surfactant contributed to the effective stabilization of solid particles by the 
adsorption of a polymer-surfactant complex on the particle.37-39)  PVP and 
sodium dodecyl sulfate (SDS) have been used in a variety of pharmaceutical 
formulations.40, 41)  The drug/PVP K17/SDS was profitably applied for the 
preparation of hydrophobic drug nanoparticles.34, 36)  The nanosuspension 
prepared from the ground mixture (GM) dispersed into distilled water exhibited 
good stability as the particle agglomeration was effectively inhibited by the 
adsorption of both PVP and SDS on the surface of crystalline particles.36)  13C 
NMR studies revealed that the nanoparticle formation and stabilization were 
attributable to grinding-induced solid-state interactions among components of 
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the drug/PVP/SDS ternary system.42-44)  The present study was designed to 
investigate the effects of particle size and PVP molecular weight on the oral 
absorption of probucol.  Pharmacokinetic profiles of probucol nanoparticles 
were evaluated after oral administration in rats.  Different sizes of probucol 
nanoparticles were produced by co-grinding with various molecular weights of 
PVP (i.e. PVP K12, PVP K17 or PVP K30) and SDS.  The Probucol/PVP/SDS 
at the weight ratio of 1:3:0.5 was employed because it was one of the most 
appropriate ratios to reduce particle size with the least ratio of SDS.42)  Effects 
of the ternary composition of the GM on the improvement of absorption were 
also discussed. 
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EXPERIMENTAL 
 
CHAPTER 1 
Stability and in vivo absorption of probucol nanoparticles 
obtained from probucol/PVP/SDS ground mixtures 
 
Materials 
Probucol, 4,4’-{(l-methylethylidene)bis(thio)}-bis{2,6-bis(l,l-dimethylethyl)} phenol, 
was supplied by Daiichi Sankyo Co., Ltd. (Tokyo, Japan).  
Polyvinylpyrrolidone, PVP K12 (MW ∼2,500), was obtained from BASF Japan 
Ltd. (Tokyo, Japan).  PVP K17 (MW ∼10,000) and PVP K30 (MW ∼50,000) 
were obtained from ISP Technologies, Inc. (Texas City, TX, USA).  Sodium 
dodecyl sulfate (SDS) was purchased from Wako Pure Chemical Industries Ltd. 
(Osaka, Japan).  These chemical structures are shown in Fig. 1.  
Hydroxypropylcellulose was purchased from Shin-Etsu Chemical Co., Ltd. 
(Tokyo, Japan).  α-Tocopherol acetate, ethyl acetate, methanol, trifluoroacetic 
acid and acetonitrile were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA).  All other chemicals used were of reagent grades. 
 
 
 
 
 
 
 Probucol 
M.W.: 516.84 
Melting point: 160 ºC 
pKa: 10.24
Sodium dodecyl sulfate (SDS)  
Anionic surfactant 
M.W.: 228.38 
Melting point: 204-207 ºC 
CMC at 25 ºC=8.15 mM＝2.0 mg/mL
Polyvinylpyrrolidone (PVP) 
Nonionic water soluble polymer 
PVP K12: M.W.: ∼2,500 
PVP K17: M.W.: ∼10,000 
PVP K30: M.W.: ∼50,000 
 
Fig. 1  Chemical structures of probucol, polyvinylpyrrolidone and sodium 
dodecyl sulfate. 
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Preparation of physical mixture (PM) 
Probucol (0.67 g), PVP (2.00 g) and SDS (0.33 g) (weight ratio of 
1:3:0.5) were physically mixed in a glass vial using a vortex mixer for 5 min 
(Fig. 2).  For the binary physical mixture, probucol (0.75 g) and PVP (2.25 g) 
or probucol (2.00 g) and SDS (1.00 g) were physically mixed following the 
same method as described above. 
 
Preparation of ground mixture (GM) 
Probucol (0.67 g), PVP (2.00 g) and SDS (0.33 g) (weight ratio of 
1:3:0.5) were physically mixed and then ground in a vibrational rod mill 
(TI-500ET, CMT Co., Ltd., Fukushima, Japan) for 30 min (Fig. 2).  The 
grinding was performed under temperature control and monitoring at 10 ± 5 °C.  
The grinding cell and rod were made of stainless steel.  For the binary ground 
mixture, probucol (0.75 g) and PVP (2.25 g) or probucol (2.00 g) and SDS (1.00 
g) were ground respectively by the same method as described above. 
 
 
 
 
 
 
 
 
 
  
 
 
Probucol SDSPVP
Grinding by vibrational rod mill
Ground mixture (GM)
Mixing at a weight 
ratio of 1:3:0.5 by vortex 
mixer
Physical mixture (PM)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2  Preparation process of probucol/PVP/SDS physical mixture and ground 
mixture. 
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Particle size analysis 
The GM was dispersed into distilled water, then sonicated for 2 min to 
make the suspension.  The drug concentration in the suspension was 0.50 
mg/mL.  The Japanese Pharmacopoeia (JP XIV) first fluid (pH 1.2) and second 
fluid (pH 6.8) were also used as liquid media instead of distilled water.  The 
particle size was determined by the dynamic light scattering method using 
Microtrac UPA, with a measurement range of 0.003-6 µm (Nikkiso Co., Ltd., 
Tokyo, Japan) and by the laser diffractive scattering method using Microtrac 
FRA, with a measurement range of 0.1-700 µm (Nikkiso Co., Ltd., Tokyo, 
Japan).  
 
Stability study 
Stability studies of the GM suspensions were investigated by particle 
size analysis after storage at 25°C for 0 (initial), 1, 2, 3, 7, 10, 12, 24 and 48 h. 
 
Quantitative determination of nanoparticles 
The GM suspensions were filtered through a 0.8 µm membrane filter 
(Millipore Corp., Tokyo, Japan) and then diluted with acetonitrile.  The 
concentration in nanoparticle fractions was determined by HPLC (LC-6A, 
Shimadzu Corp., Kyoto, Japan).  The mobile phase (acetonitrile/water = 
185/15, v/v) was delivered at a flow rate of 1.0 mL/min through a C-18 column 
(Inertsil ODS-2, 5 µm, 4.5 x 150 mm, GL Sciences Inc., Tokyo, Japan) at 40 °C 
and the detection wavelength was 220 nm.  The concentrations of probucol in 
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the samples were determined by the linear equation obtained from the standard 
curve(y =26088x-2223, correlation coefficient =0.9999). 
 
In vivo absorption study 
Probucol formulations were administered by oral gavages to male 
Sprague Dawley rats. Twenty-seven adult rats with a weight of 270-330 g were 
obtained from Charles River Laboratories Inc. (Wilmington, MA, USA).  All 
rats were made to fast overnight prior to the dose administration and remained 
fasting until 6 h after the dose administration.  The sample suspensions were 
prepared with sonication by dispersing the probucol formulations into distilled 
water to obtain a probucol concentration of 25 mg/mL, and then administered to 
the rats at 8 mL/Kg by oral gavage.  In the case of unprocessed probucol, due 
to its low wettability, 0.5% hydroxypropylcellulose solution was used instead of 
distilled water to facilitate the dispersion.  Blood samples (∼0.3 mL) were 
collected into vacutainer tubes containing EDTA, 0, 1, 2, 3, 4, 7, 10, 24 and 48 h 
after drug administration.  After this collection, the blood samples were 
centrifuged at approximately 2800 rpm (∼1000 x g) at 2-8 °C for about 15 min.  
Each plasma specimen was collected, and stored at ∼ -80 °C until analysis.  No 
adverse reaction was observed following dose administration during the study.   
  
Determination of probucol in rat plasma by HPLC 
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Preparation of plasma samples 
Probucols in the plasma samples were determined by HPLC.45-47)  
α-Tocopherol acetate was used as internal standard.48)  A solution of internal 
standard was prepared with ethyl acetate at 10 µg/mL.  Samples were prepared 
as follows: 50 µL of plasma were extracted with 1 mL of internal standard 
solution in polypropylene tubes.  Samples were then sonicated for 5 min, 
vortexed for 5 min and centrifuged at 12,000 rpm for 10 min.  Supernatants 
were transferred into glass test tubes.  A blank (50 µL of blank plasma 
extracted with internal standard) and double blank (50 µL of blank plasma 
extracted with blank ethyl acetate) were also prepared.  Samples were dried 
under nitrogen, reconstituted with 100 µL of methanol, and transferred into a 
glass insert in an autosampler vial.  The plasma sample preparation scheme is 
shown in Fig. 3. 
 
 
 
 
 
 
 
 
 
  
 50μL of plasma
(Plastic tube)
1mL of Internal Standard solution
Sonication for 5 min
Vortex for 5 min
Centrifuge at 12,000 rpm for 10 min
Dried with N2
HPLC assay
Supernatants
(Glass tube)
Add 100μL of Me-OH and 
transfer solution to HPLC Vial
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3  The plasma sample preparation scheme. 
 
- 12 - 
 Preparation of standard samples 
Standards were prepared in the same manner as samples (using blank 
plasma) and reconstituted with methanol containing probucol at known 
concentrations.  Eight calibration standards were prepared for probucol 
concentration in plasma, between 0.02 and 8.75 µg/mL probucol in plasma.  
The limit of quantitation was described by the lowest concentration of the 
standard (0.02 µg/mL).  
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(The graph of the linear standard curve) 
 
HPLC conditions 
The probucol concentration in plasma samples was determined by HPLC 
(HP 1100, Agilent Technologies Inc., Santa Clara, CA, USA). 45-47)  The mobile 
phase was delivered at a flow rate of 1.5 mL/min through a reverse-phase 
column (Zorbax 300SB-C8, 5 µm, 4.6 x 150 mm, Agilent Technologies Inc., 
Santa Clara, CA, USA) at 40 °C and the detection wavelength was 220 nm.  
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The injection volume was 20 µL.  The gradient was the change in the 
proportion of phase A solvent (0.1% trifluoroacetic acid in water) and phase B 
solvent (0.1% trifluoroacetic acid in acetonitrile) that make up the mobile phase.  
The steps of gradient shown were: phase B solvent concentration in the mobile 
phase was 75% (at 0 min) and changed from 75% to 90% (after 10 min) and 
returned from 90% to 75% (after 15 min).  A representative chart sample is 
shown in Fig. 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig. 4  A representative HPLC chart, probucol retention time is around 3.4 
min. 
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HPLC data analysis 
Analysis of the plasma samples was carried out using Agilent Chem 
Station software (V. A. 09. 01, Agilent Technologies Inc., Santa Clara, CA, 
USA).  The concentrations of probucol in the samples were determined by the 
linear equation obtained from the standard curve(y=0.0157x+0.0007, correlation 
coefficient =0.9987). 
 
Statistic analysis 
Data are expressed by the mean ± S.E..  The area under the plasma 
concentration-time curve (AUC) value (0-48 h) of the plasma profiles was 
calculated using the logarithmic and linear trapezoidal rules.  P-values were 
calculated using F-test and T-test in Microsoft Excel 2003 and less than 0.05 
considered significant.  
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CHAPTER 2 
 In vivo comparison in the case that the particle size 
obtained from ternary GM with PVP K12 is larger than 
that from ternary GM with PVP K17 
 
Materials 
Ingredients used in chapter 2 were the same as those described in 
materials in chapter 1. 
 
Preparation of ground mixture (GM) with PVP K12 (40nm) 
Probucol (0.67 g), PVP K12 (2.00 g) and SDS (0.33 g) (weight ratio of 
1:3:0.5) were physically mixed and then ground in a vibrational rod mill 
(TI-500ET, CMT Co., Ltd., Fukushima, Japan) for the certain time to adjust the 
particle size in suspension to 40nm.  The grinding was performed under 
temperature control and monitoring at 10 ± 5 °C.  The grinding cell and rod 
were made of stainless steel. 
 
Preparation of ground mixture (GM) with PVP K17 (36nm) 
Probucol (0.67 g), PVP K17 (2.00 g) and SDS (0.33 g) (weight ratio of 
1:3:0.5) were physically mixed and then ground in a vibrational rod mill 
(TI-500ET, CMT Co., Ltd., Fukushima, Japan) for 30 min.  The grinding was 
performed under temperature control and monitoring at -180 ± 5 °C.  The 
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grinding cell and rod were made of stainless steel. 
 
In vivo absorption study 
In vivo absorption study was conducted in a manner similar to the study 
method described in in vivo absorption study in chapter 1, but six adult rats with 
a weight of 350-400 g were obtained from Charles River Laboratories Inc. 
(Wilmington, MA, USA).  No adverse reaction was observed following dose 
administration during the study. 
  
Determination of probucol in rat plasma by HPLC 
Preparation of plasma samples 
Plasma samples were prepared in a manner similar to the method 
described in preparation of plasma samples in chapter 1.  
  
Preparation of standard samples 
Standards were prepared in the same manner as samples (using blank 
plasma) and reconstituted with methanol containing probucol at known 
concentrations.  Five calibration standards were prepared for probucol 
concentration in plasma, between 0.05 and 4.00 µg/mL probucol in plasma.  
The limit of quantitation was described by the lowest concentration of the 
standard (0.05 µg/mL).  
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(The graph of the linear standard curve) 
 
HPLC conditions 
The probucol concentration in plasma samples was determined by HPLC 
(HP 1200, Agilent Technologies Inc., Santa Clara, CA, USA). 45-47)  The mobile 
phase was delivered at a flow rate of 1.5 mL/min through a reverse-phase 
column (Zorbax 300SB-C8, 5 µm, 4.6 x 150 mm, Agilent Technologies Inc., 
Santa Clara, CA, USA) at 40 °C and the detection wavelength was 220 nm.  
The injection volume was 20 µL.  The gradient was the change in the 
proportion of phase A solvent (0.1% trifluoroacetic acid in water) and phase B 
solvent (0.1% trifluoroacetic acid in acetonitrile) that make up the mobile phase.  
The steps of gradient shown were: phase B solvent concentration in the mobile 
phase was 75% (at 0 min) and changed from 75% to 90% (after 10 min) and 
returned from 90% to 75% (after 15 min). 
 
HPLC analysis 
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Analysis of the plasma samples was carried out using Agilent Chem 
Station for LC 3D systems software (Rev. 13. 02. 01, Agilent Technologies Inc., 
Santa Clara, CA, USA).  The concentrations of probucol in the samples were 
determined by the linear equation obtained from the standard 
curve(y=0.2807x+0.005, correlation coefficient =0.9997). 
 
Data analysis 
Data are expressed by the mean ± S.E..  The area under the plasma 
concentration-time curve (AUC) value (0-48 h) of the plasma profiles was 
calculated using the logarithmic and linear trapezoidal rules. 
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RESULTS AND DISCUSSION 
 
CHAPTER 1 
Stability and in vivo absorption of probucol nanoparticles 
obtained from probucol/PVP/SDS ground mixtures 
 
1. Stability study of probucol/PVP/SDS ternary GM suspension 
The mixing ratio of probucol/PVP/SDS at the weight ratio of 1:3:0.5 
was employed for ternary ground mixtures (GMs) and ternary physical mixtures 
(PMs) in this study, in order to reduce the amount of excipients and the 
administration volume though our previous experiments confirmed that the best 
suitable ratio was 1:3:1.42)  
Variations in particle size of probucol obtained from probucol/PVP/SDS 
ternary GMs dispersed into distilled water and physiological fluids, JP XIV first 
fluid (pH 1.2) and JP XIV second fluid (pH 6.8), are shown in Fig. 5.  After 
dispersion into distilled water, the initial particle sizes of probucol nanoparticles 
obtained from probucol/PVP K12/SDS, probucol/PVP K17/SDS and 
probucol/PVP K30/SDS ternary GMs were 28, 75 and 89 nm, respectively.  
During the storage period, the size of probucol nanoparticles obtained from the 
ternary GM prepared with PVP K12 increased steadily, while those of the 
ternary GMs prepared with PVP K17 and PVP K30 showed slight increases 
only in the initial stage then became constant.  Finally, the particle size of the 
ternary GM with PVP K12 was higher than that of the ternary GMs prepared 
with PVP K17 or PVP K30. 
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Fig. 5  Variation in the particle size of probucol nanoparticles obtained from 
ternary ground mixtures of probucol/PVP/SDS at the weight ratio of 1:3:0.5 
after dispersion in (A) distilled water, (B) JP first fluid and (C) JP second fluid, 
at various time intervals and at a temperature of 25 °C. 
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The initial probucol particle size of the ternary GM with PVP K12 
increased from 28 nm in distilled water to 48 nm in JP first fluid, and 56 nm in 
JP second fluid.  In contrast, the particle size obtained from the ternary GMs 
with PVP K17 and PVP K30 slightly decreased from 75 and 89 nm in water to 
69 and 81 nm in JP first fluid, and 75 and 85 nm in JP second fluid, respectively.  
Changes in the particle size with time, for all ternary GMs, exhibited a 
comparable trend regardless of the dispersion media.  The results demonstrated 
that the probucol particle size was effectively reduced at the initial stage when 
the low molecular weight PVP was employed.  In pH-adjusted conditions, the 
particle size of probucol prepared with PVP K12 became large, while the other 
two PVPs showed little influence on the particle size.  It was assumed that the 
surface conditions of nanoparticles obtained from PVP K12/SDS might be 
different from those of PVP K17/SDS and PVP K30/SDS.  It was clarified that 
SDS formed micelles together with the PVP polymer as a micelle-like aggregate 
in PVP/SDS solution.49-57)  For the ternary GMs with PVP K17 and PVP K30, 
the surfaces of probucol nanoparticles were probably covered by PVP-SDS 
micelle complex as a layered structure, so that ternary GMs with PVP K17 and 
PVP K30 were able to become stable in the suspensions.  For the ternary GM 
with PVP K12, PVP K12 and SDS might not make a PVP-SDS complex with 
micelle-like structure, due to the shortest length of the chain (the molecular 
weight was 1/4 of PVP K17, 1/20 of PVP K30).  The PVP K12 and SDS might 
cover insufficiently the surface of probucol nanoparticles in the suspension.  
Therefore ternary GM with PVP K12 induced a relatively rapid agglomeration 
of probucol nanoparticles.  Possible models of the probucol nanoparticle 
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formation from the probucol/PVP/SDS GMs52) are shown in Fig. 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Insufficient surface coverage 
with PVP K12 and SDS of 
probucol nanoparticles
SDS moleculeProbucol nanoparticle PVP polymer
Ternary GMs with PVP K17 and with PVP K30 are dispersed into water.
∼90 nm
(Probucol/PVP K17/SDS GM and Probucol/PVP K30/SDS GM)
Ternary GM with PVP K12 is dispersed into water.
(Probucol/PVP K12/SDS GM)
∼30 nm
PVP-SDS complex with 
micelle-like structure.
 
Reference; Pongpeerapat et al., Int. J. Pharm., in press (2008) 
Fig. 6  Possible models of the formation of probucol nanoparticles from the 
ternary GMs with PVP and SDS. 
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2. Drug absorption from the ternary GM 
Pharmacokinetics of different probucol formulations administered by 
oral gavages to male Sprague Dawley rats was evaluated.  The plasma 
concentration-time profiles of probucol after oral administration in rats are 
shown in Fig. 7.  The in vivo absorptions were remarkably improved by 
probucol/PVP/SDS ternary GMs compared to those of the ternary PM and 
unprocessed probucol.  After the administration of ternary GMs, the plasma 
concentrations increased rapidly and peaks were observed after 3-4 h.  
Pharmacokinetic parameters following oral administration of the 
probucol/PVP/SDS ternary GM suspensions are presented in Table 1.  
Interestingly, the suspension obtained from the ternary GM prepared with PVP 
K12 remarkably increased AUC and the maximum drug concentration (Cmax) 
values of probucol, 41.3-fold (P < 0.005) and 17.0-fold (P < 0.005) compared to 
the respective values of unprocessed probucol.   For ternary GMs with PVP 
K17 and PVP K30 cases, the AUC and Cmax values increased 10.7-fold (P < 
0.05) and 7.7-fold (P < 0.02), 5.6-fold (P < 0.05) and 3.3-fold (P < 0.02), 
respectively.  There were no significant differences in AUC and Cmax values 
between the ternary PM and the unprocessed probucol.  These results 
suggested that additives used have no effect on in vivo absorption of the 
unprocessed probucol. 
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Fig. 7  Effects of molecular weight of PVP on plasma concentration of 
probucol following oral administration of the probucol/PVP/SDS ternary 
ground mixture suspension.  Results are expressed as mean ± S.E. (n = 3). 
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Table 1  Pharmacokinetic parameters of probucol following oral administration 
of probucol/PVP/SDS ternary suspensions.  
Suspension Cmax (µg/mL) Tmax (h) AUC (µg h/mL) Enhancement 
ratioa
Unprocessed probucol 0.07 ± 0.01 3.7 ± 0.3 0.31 ± 0.02 1.0 
Probucol/PVP K12/SDS GM 1.19 ± 0.06*** 4.0 ± 0.0 12.81 ± 0.77*** 41.3 
Probucol/PVP K17/SDS GM 0.54 ± 0.06** 3.0 ± 0.6 3.33 ± 0.49* 10.7 
Probucol/PVP K30/SDS GM 0.23 ± 0.03** 3.3 ± 0.3 1.74 ± 0.22* 5.6 
Probucol/PVP K12/SDS PM 0.05 ± 0.00 3.7 ± 0.3 0.54 ± 0.15 1.7 
Cmax = maximum drug concentration, Tmax = time of maximum concentration, 
AUC= area under the plasma concentration-time curve. 
Results are expressed as mean ± S.E. (n = 3).  
a Enhancement ratio was calculated according to the following equation: 
The ratio = The corresponding AUC/AUC of unprocessed probucol. 
***P<0.005; **P<0.02; *P<0.05, compared to the corresponding parameters of 
the unprocessed probucol suspension. 
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The particle size reduction could lead to the enhancement of the in vivo 
absorption of probucol.  But stability results shown in Fig. 5 demonstrated that 
the probucol particle obtained from ternary GM with PVP K12 has different 
characteristics from those of ternary GMs with PVP K17 and PVP K30.  Not 
only the size of probucol nanoparticles but also the different surface states 
covered by PVP and SDS seemed to influence the in vivo absorption of 
probucol.  Despite the fact that the particle size obtained from the ternary GM 
with PVP K17 was somewhat similar to that from the ternary GM with PVP 
K30, ternary GM with PVP K17 enhanced the absorption better than the ternary 
GM with PVP K30.  It was considered that the long chain length of high 
molecular weight PVP (PVP K30) contributed to the thick layer structure of the 
PVP/SDS complex on the surface of nanoparticles.  The thick layer structure 
might be attributed to the difficulty of probucol molecules to be dissolved and 
absorbed.  On the contrary, the smallest nanoparticles without the layer 
structure, which were generated by ternary GM with PVP K12, might facilitate 
dissolution and absorption, though the stability in water is not so good as shown 
in Fig. 5. 
 Palin and Wilson reported co-administration with arachis oil enhanced 
the in vivo absorption of probucol in rats which AUC0-16 value was 11.74±1.55 
µg h/mL.12)  Generally, oil dissolution system has an advantage for lipophilic 
drug absorption,58) however this study clarified that water dispersion with 
ternary GM with PVP K12 even improved the in vivo absorption of probucol as 
the comparison in AUC between ternary GM with PVP K12 and arachis oil.  
Furthermore, it is understood that ternary GM with PVP K12 can also enhance 
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the absorption speed of probocol because more than 0.4 µg/mL plasma 
concentration was observed at 1 hour after the administration despite the plasma 
concentration from arachis oil was below the detection limit. 
 
3. Investigation of drug absorption from binary GM with SDS 
The effects of probucol/PVP K12 and probucol/SDS binary GMs on 
plasma concentration of probucol through oral administration of the suspension 
are shown in Fig. 8.  The probucol/PVP K12 binary GM demonstrated a 
similar pharmacokinetics profile to that of the binary PMs and unprocessed 
probucol.  On the other hand, the probucol/SDS binary GM showed small 
absorption improvement compared to all other binary mixtures and the 
unprocessed probucol.  Table 2 also presents pharmacokinetic parameters of 
binary systems.  The AUC and Cmax values of the probucol/SDS GM increased 
3.5-fold (not statistically significant) and 2.4-fold (P < 0.005) compared to the 
unprocessed probucol, respectively. 
Mean particle sizes of probucol obtained from the binary systems and 
ternary PM are shown in Table 3.  The size of the unprocessed probucol was 
27.7 µm.  Probucol/PVP K12 and probucol/SDS GMs showed no significant 
particle size reduction compared to the unprocessed probucol even though 
absorption improvement in probucol/SDS GM was observed.  However, there 
still remains the possibility that the particle size in the range of the submicron 
region might not be detected due to the detection limit of the FRA particle size 
analyzer.  A filtrate sample of the probucol/SDS GM suspension was prepared 
with a 0.8 µm membrane filter to investigate whether the micronized particles 
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exist or not.  HPLC quantitative analysis revealed that approximately 17% of 
the probucol was recovered as nanometer-sized particles in the suspension of 
probucol/SDS binary GM.  The average particle size was around 287 nm.  
These results supported the reason that there was insignificant absorption 
improvement derived from the probucol/SDS binary GM.  Because probucol 
nanoparticles from the probucol/SDS binary GM were unstable in JP first 
fluid,36) their structures were different from those of ternary GMs, which were 
covered with PVP and SDS. 
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Fig. 8  Effects of grinding with PVP K12 or SDS on plasma concentration of 
probucol following oral administration of the suspension.  Results are 
expressed as mean ± S.E. (n = 3). 
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Table 2  Pharmacokinetic parameters of probucol following oral administration 
of probucol/PVP and probucol/SDS binary suspensions. 
Suspension Cmax (µg/mL) Tmax (h) AUC (µg h/mL) Enhancement 
ratioa
Unprocessed probucol 0.07 ± 0.01 3.7 ± 0.3 0.31 ± 0.02 1.0 
Probucol/PVP K12 PM 0.06 ± 0.00 3.3 ± 0.7 0.36 ± 0.06 1.2 
Probucol/PVP K12 GM 0.05 ± 0.00 2.7 ± 0.3 0.53 ± 0.16 1.7 
Probucol/SDS PM 0.05 ± 0.00 3.7 ± 0.3 0.49 ± 0.05 1.6 
Probucol/SDS GM 0.17 ± 0.01* 3.0 ± 0.0 1.09 ± 0.21 3.5 
Cmax = maximum drug concentration, Tmax = time of maximum concentration, 
AUC= area under the plasma concentration-time curve. 
Results are expressed as mean ± S.E. (n = 3). 
a Enhancement ratios were calculated according to the following equation: 
The ratio = The corresponding AUC/AUC of unprocessed probucol. 
*P<0.05 compared to the corresponding parameters of the unprocessed 
probucol suspension. 
 
 
 
- 34 - 
 
 
 
 
 
 
Table 3  Mean particle size of probucol obtained from the binary and ternary 
physical mixtures and ground mixtures in distilled water, measured by FRA 
(0.1-700 µm). 
Suspension Mean particle size (µm) 
Unprocessed probucol 27.7 ± 0.6 
Probucol/PVP K12 PM  42.3 ± 0.4 
Probucol/PVP K12 GM  17.3 ± 0.4 
Probucol/SDS PM  46.0 ± 0.3 
Probucol/SDS GM 58.4 ± 2.4 
Probucol/PVP K12/SDS PM 47.1 ± 0.1 
Probucol/PVP K12/SDS GM 0.028 ± 0.001a
Results are expressed as mean ± S.D. (n = 3). 
a Particle size was measured by UPA (0.003-6 µm). 
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CHAPTER 2 
In vivo comparison in the case that the particle size 
obtained from ternary GM with PVP K12 is larger than 
that from ternary GM with PVP K17 
 
1. Verification of the effect of nanoparticle surface condition with PVP and 
SDS on the absorption 
Probucol in vivo absorption rate was remarkably improved by ternary 
GM with PVP K12 compared to that of ternary GM with PVP K17 due to its 
smallest particle size in chapter 1.  But, insufficient surface coverage with PVP 
K12 and SDS of the particles in the suspension also seemed to enhance the in 
vivo absorption of probucol.  To evaluate if both of smallest particle size and 
insufficient surface coverage influence the absorption improvement, ternary 
GMs with PVP K12 and with PVP K17, which can generate smaller particle 
size than PVP K12 in suspension, were prepared.  Specially, ternary GM with 
PVP K17 was ground under the temperature of -180 °C to reduce the size under 
50 nm.  In chapter 2, the nanoparticles obtained from ternary GMs with PVP 
K12 and with PVP K17 in suspensions were 40 nm and 36 nm, respectively. 
Pharmacokinetic parameters following oral administration of the 
probucol/PVP/SDS ternary GM suspensions are presented in Table 4A.  The 
AUC and Cmax values of probucol from ternary GM with PVP K12 were 23.64 
µg h/mL and 1.61 µg/mL, respectively.  For the ternary GM with PVP K17 
case, the AUC and Cmax values were 13.42 µg h/mL and 1.29 µg/mL, 
respectively.  
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Table 4  The percentage of pharmacokinetic parameters of probucol/PVP 
K17/SDS GM in probucol/PVP K12/SDS GM on (A) in vivo absorption study 
in chapter 2 and (B) in vivo absorption study in chapter 1. 
(A) 
Probucol/PVP K12/SDS GM 
(40nm) 
Probucol/PVP K17/SDS GM 
(36nm)  Percentage (%)
a
AUC (µg h/mL) 23.64 ± 7.19 13.42 ± 1.11 56.77 
Cmax (µg/mL) 1.61 ± 0.48  1.29 ± 0.07 80.12 
 
(B) Probucol/PVP K12/SDS GM 
(28nm) 
Probucol/PVP K17/SDS GM 
(75nm)  Percentage (%)
a
AUC (µg h/mL) 12.81 ± 0.77  3.33 ± 0.49 26.00 
Cmax (µg/mL) 1.19 ± 0.06 0.54 ± 0.06 45.38 
AUC= area under the plasma concentration-time curve, Cmax = maximum drug 
concentration. 
Results are expressed as mean ± S.E. (n = 3).  
a The percentage was calculated according to the following equation: 
The value = AUC or Cmax of Probucol/PVP K17/SDS GM divided by 
AUC or Cmax of Probucol/PVP K12/SDS GM multiplied by 100. 
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However, the PK results in chapter 2 (Table 4A) were unexpectedly 
higher than those in chapter 1 (Table 4B).  It might be the reason that the 
stronger feeding impact begun 6 h after the dose administration influenced the 
increasing of in vivo probucol absorption in chapter 2.12)  Therefore the PK 
values were converted into percentage values in order to compare the results 
between chapter 2 and chapter 1, because the results in chapter 2 could not be 
compared directly with those in chapter 1.  Higher percentage value means the 
absorption improvement obtained from ternary GM with PVP K17 approaches 
or overtakes that from ternary GM with PVP K12. 
In chapter 2, the percentages of AUC and Cmax values obtained from 
ternary GM with PVP K17 (36nm) in those of ternary GM with PVP K12 
(40nm) were 56.77 % and 80.12 %, respectively.  On the contrary, in chapter 1, 
the percentages of AUC and Cmax values obtained from ternary GM with PVP 
K17 (75nm) in those of ternary GM with PVP K12 (28nm) were 26.00 % and 
45.38 %, respectively, as shown in Table 4.  These results suggested that 
smaller particle size with PVP K17 (75nm→36nm) may influence the higher 
absorption improvement (AUC: 26.00→56.77 %, Cmax: 45.38→80.12 %).  
Moreover, it might be clarified that insufficient surface coverage of the probucol 
nanoparticles with PVP K12 and SDS in the suspension plays an important role 
in enhancing in vivo drug absorption because the AUC value (23.64 µg h/mL) 
derived from ternary GM with PVP K12 can still overtake the value (13.42 µg 
h/mL) derived from ternary GM with PVP K17 even the particle size (40nm) is 
larger than PVP K17 (36nm). 
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CONCLUSION 
 
It was demonstrated that the ternary ground mixtures of 
probucol/PVP/SDS significantly enhanced the bioavailability of probucol.  The 
ternary GM with PVP K12 showed a superior absorption improvement 
compared to the GMs with PVP K17 and PVP K30.  The results suggested that 
not only reduced particle size of probucol but also different particle surface 
conditions covered with PVP and SDS could influence the in vivo absorption of 
probucol.  On the contrary, the ternary PM and all binary GMs did not show 
significant differences in the AUC value compared to the unprocessed probucol.  
Preparation of probucol nanoparticles by co-grinding with PVP K12 and SDS 
was confirmed as the promising method for the bioavailability enhancement. 
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